TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05408832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Trial ABCCBA
Description: Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (ABCCBA), where A=mindfulness meditation, B=yoga, and C=brisk walking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Trial CBAABC
Description: Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A=mindfulness meditation, B=yoga, and C=brisk walking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Techniques with No Randomization Sequence (or order)
Description: Participants will have access to all 30-minute videos for A=mindfulness meditation, B=yoga, and C=brisk walking, during the 12-week phase of the study. They will be limited to 12 total views per stress management technique.
Study: NCT06406179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dd-cfDNA-guided
Description: patients will follow an dd-cfDNA-guided strategy based on dd-cfDNA for immune monitoring; blood will be sampled at D0 only for patients with previous kidney transplant, at the M3 and M12 visits and at the visits for clinical indication (3 maximum ) and the blood shipped to PARCC INSERM UMR 970 technical platform. Combining dd-cfDNA level and relevant medical data, an integrative report will be sent to the centers stratifying patients into high- versus low-risk profiles of rejection.~Patients stratified into a high-risk profile of rejection according to the report will undergo an allograft biopsy in the following 15 days after sampling; patients stratified into a low-risk profile of rejection will not undergo the biopsy.
Study: NCT04849351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-689
Description: All patients are to receive monotherapy of HMPL-689 30 mg QD continuously in 28-day treatment cycles.
Study: NCT06416709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Mesenchymal stem cell dose is 5×10\*7/10ml and is transplanted by intravenous infusion. The cells are used once every three days and for three times

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 10 ml saline is used as placebo once every three days and for three times
Study: NCT05998161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reviga
Description: Participants will receive access to the digital health intervention reviga in addition to TAU.
Study: NCT04837820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Acupuncture
Description: Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wait-List Control (WLC)
Description: Patients in the WLC group will continue to receive their standard medical care as prescribed by their oncologists/primary care physicians.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Will follow patients for 26 weeks from baseline and collect assessments at baseline and Weeks 0, 10, and 26. Average time to complete the surveys is 30 minutes, which has been judged to be acceptable with minimal missing data; 20 minutes of these 30 minutes will be completed during the neurocognitive battery. Patients will complete PROs online using Research Electronic Data Capture (REDCap) or over the phone with the CRC. Biospecimens will be collected in person at assessment visits. The neurocognitive battery will be administered remotely.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Will follow patients for 26 weeks from baseline and collect assessments at baseline and Weeks 0, 10, and 26. Average time to complete the surveys is 30 minutes, which has been judged to be acceptable with minimal missing data; 20 minutes of these 30 minutes will be completed during the neurocognitive battery. Patients will complete PROs online using Research Electronic Data Capture (REDCap) or over the phone with the CRC. Biospecimens will be collected in person at assessment visits. The neurocognitive battery will be administered remotely.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Will follow patients for 26 weeks from baseline and collect assessments at baseline and Weeks 0, 10, and 26. Average time to complete the surveys is 30 minutes, which has been judged to be acceptable with minimal missing data; 20 minutes of these 30 minutes will be completed during the neurocognitive battery. Patients will complete PROs online using Research Electronic Data Capture (REDCap) or over the phone with the CRC. Biospecimens will be collected in person at assessment visits. The neurocognitive battery will be administered remotely.
Study: NCT06324799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phototherapy treatment
Description: The newborns in the study group will be subjected to position changes (supine, prone, lateral) every 2 hours
Study: NCT05571345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614
Description: PF614 capsules (50 mg or 100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614
Description: PF614 capsules (50 mg or 100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614
Description: PF614 capsules (50 mg or 100 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Hydrochloride 40 mg
Description: Oral 20 mg tablets (two each)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match PF614 capsules will be provided by the sponsor.
Study: NCT05812833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Pregnant women will be given online baby care training
Study: NCT05569772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Pen Injector
Description: maintenance dose of 1mg SC once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide placebo
Description: maintenance dose of 1mg SC once weekly
Study: NCT05786495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Discontinuation of Antibiotics
Description: Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be stopped after 72 hours of treatment and defervescence for 24 hours, irrespective of neutrophil count

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be continued until resolution of neutropenia
Study: NCT05538559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemomechanical caries removal by Carie-Care
Description: caries in primary teeth will be removed using Carie-Care™ the chemomechanical agent.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical caries removal by Atraumatic Restorative Technique
Description: caries in primary teeth will be removed using the mechanical caries removal by ART method.
Study: NCT05614986

Intervention type: OTHER
Intervention: 5 minute Montreal Cognitive Assessment (mini MoCA)
Description: The mini MoCA will be completed by the patient before TAVR, and 30 days and 6 months after TAVR
Study: NCT04837937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Patient [Beginner]
Description: Participants will be assigned a 'Caregiver vs. Patient' \[Beginner\] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Patient [Beginner]
Description: Participants will be assigned a 'Caregiver vs. Patient' \[Beginner\] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.
Study: NCT04485858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorNeat KPro
Description: CorNeat KPro will be implanted into the subject's eye where the optic component snaps into the patient's trephined cornea and is sutured to the eye wall using 3 non-degradable sutures and the skirt component is placed under the conjunctiva
Study: NCT04837937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Patient [Beginner]
Description: Participants will be assigned a 'Caregiver vs. Patient' \[Beginner\] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Caregiver
Description: Participants will be assigned a 'Caregiver vs. Caregiver' online negotiation exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Caregiver
Description: Participants will be assigned a 'Caregiver vs. Caregiver' online negotiation exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Caregiver
Description: Participants will be assigned a 'Caregiver vs. Caregiver' online negotiation exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Caregiver
Description: Participants will be assigned a 'Caregiver vs. Caregiver' online negotiation exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Physician
Description: Participants will be assigned a 'Caregiver vs. Physician' online negotiation exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Physician
Description: Participants will be assigned a 'Caregiver vs. Physician' online negotiation exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Physician
Description: Participants will be assigned a 'Caregiver vs. Physician' online negotiation exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Physician
Description: Participants will be assigned a 'Caregiver vs. Physician' online negotiation exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Patient [Advanced]
Description: Participants will be assigned a 'Caregiver vs. Patient \[Difficult\]' online negotiation exercise. This exercise is advanced compared to the constant since it involves negotiating more than one conflict.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Patient [Advanced]
Description: Participants will be assigned a 'Caregiver vs. Patient \[Difficult\]' online negotiation exercise. This exercise is advanced compared to the constant since it involves negotiating more than one conflict.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Patient [Advanced]
Description: Participants will be assigned a 'Caregiver vs. Patient \[Difficult\]' online negotiation exercise. This exercise is advanced compared to the constant since it involves negotiating more than one conflict.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver vs. Patient [Advanced]
Description: Participants will be assigned a 'Caregiver vs. Patient \[Difficult\]' online negotiation exercise. This exercise is advanced compared to the constant since it involves negotiating more than one conflict.
Study: NCT05195229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVID-19 Aerosol Collection
Description: Step 1: A nasal and oral swab will be obtained to establish the nasopharyngeal viral load.~Step 2: Study staff will use the CCI and/or UPAS to collect aerosol samples for viral load. Staff will sample the room aerosol for 30 minutes while the participant does not wear a mask, and then if the participant is interested, staff will sample room aerosol while the participant wears different types of masks. If the participant does not tolerate wearing a surgical mask, or if the providers believe this is contraindicated, researchers will forego this portion of the study procedures. If an accompanying family member chooses to stay in the patient room during testing, they will be provided with an N95 respirator.
Study: NCT06594783

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol plus endoscopic variceal ligation
Description: Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carvedilol alone
Description: Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable).
Study: NCT06609967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: application of PRF
Description: PRF will be randomly administered into one group of patients undergoing any extractions group A (Right after the extraction) Group B will be a control group in which extraction sockets will be left to heal with the natural blood clot. Consenting patients will be assigned into groups randomly and not informed which group they were placed into. The PRF will be administered obtained from a tube of 10 ml blood and no material will be placed in the control group. The progress of healing and post-operative complications will be tracked over a period of 7 days with patients being called for follow-up on days 3, 5 and 7

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: application of conventional surgicel
Description: it will be a control group in which extraction sockets will be left to heal with the natural blood clot.
Study: NCT06610318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: imagery rescripting
Description: This condition has three stages. In the first stage, participants were asked to select their most distressing memory related to their appearance (not physical or sexual trauma). They were asked to visualize the selected memory, in detail, as if it were happening to them again. Then, interventionists used a downward arrow technique to identify two-to-three maladaptive core schema. In the second stage, participants were asked to identify a real or imagined trusted adult. Then, they were asked to imagine what their younger self might need to cope with or feel calmer in the situation of their selected memory. In the third stage, the participant was instructed to imagine asking the trusted adult for what they need and to imagine the trusted adult providing their selected interventions and describe how they feel afterwards. These procedures were then repeated with participants' most distressing memory related to eating. This session was remote delivered via Zoom.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutrition education
Description: The active control condition consisted of a time- and attention-matched general nutrition education session. The curriculum for this intervention included information from the United States Department of Agriculture's Dietary Guidelines (e.g., food labels, describing the benefits of macronutrients). This session was remote delivered using Zoom.
Study: NCT06609785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The volunteers successively completed both high intensity interval training (HIIT)and continuous aerobic training (CAT) under the supervision of a professional coach, and the interval between each type of exercise was 7 days. Each training session was initiated with a brief 2-minute standardized warm-up, followed by 20 minutes of cycling consisting of periods of 2 minutes at 80-95% maximal heart rate (HRmax) separated by 2 minutes of active recovery for the HIIT group or 20 minutes of cycling at 60-80% of HRmax for the CAT group.
Study: NCT06610123

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine and Resistance training
Description: Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine and Resistance training
Description: Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine and Resistance training
Description: Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine and Resistance training
Description: Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Resistance training
Description: Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Resistance training
Description: Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Resistance training
Description: Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Resistance training
Description: Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
Study: NCT05597774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory + expiratory muscle training group
Description: Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory + expiratory muscle training sham group
Description: Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: Participants will perform a cardiovascular exercise program including warm-up, recovery between intervals and return to calm by cycloergometer.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise training program
Description: Participants will perform a cardiovascular exercise program including warm-up, recovery between intervals and return to calm by cycloergometer.
Study: NCT05445895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renexin CR 200/160mg
Description: Renexin CR 200/160mg will be added to Aspirin 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix 75mg
Description: Plavix 75mg will be added to Aspirin 100mg
Study: NCT06209333

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Patient Education
Description: Standard Patient Education will take approximately 20 minutes. Within the scope of standard patient education, some recommendations will be made to the patient to lose weight, drink sufficient water, avoid consuming caffeinated foods and beverages, acidic/carbonated or alcoholic beverages, spicy/acidic foods, and quit smoking. Patients will be evaluated on the day they receive standard patient training (before receiving this training) and 10 weeks after the training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bladder training
Description: Interval urination in bladder training in bladder training will be determined according to the bladder diaries filled in by the patients. If the patient is able to do it, bladder education will be improved by increasing the interval urination in bladder training. A total of 5 sessions of bladder training will be applied to patients, the first session of which will be face-to-face. Within the scope of Bladder Training, the patient will be given information about bladder, pelvic floor, incontinence and relaxation techniques. The patient will be asked to fill out a 3-day bladder diary before starting bladder training, and an appropriate progressive timed voiding program will be drawn according to the bladder diaries, and the patient will be given a training brochure to implement this program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor exercise
Description: This training will take between 45 and 60 minutes.Within the scope of exercise training, patients will be taught 3 types of contractions: maximal (fast), slow and submaximal contractions. The patient will be asked to continue the maximum and submaximal contraction for 1-2 seconds, and to continue the Deceleration contraction for 3-10 seconds. These contractions will be performed in different positions such as supine, lying on the side, sitting, crawling, squatting and standing, specifically for the pelvic floor November muscle strength of the patient. These exercises will be performed every day and each type of contraction (maximal, slow and submaximal contraction) will be performed 8-12 repetitions, 3 sets per day. Progress will be achieved with follow-ups.
Study: NCT05749484

Intervention type: OTHER
Intervention: NCRT+TME
Description: The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
Study: NCT04894110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EO2002
Description: EO2002 (magnetic human corneal endothelial cells \[HCECs\]) with and without endothelial brushing (EB) or Descemet Stripping (DS)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EO2002 low dose
Description: Low dose of EO2002 (magnetic human corneal endothelial cells)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EO2002 mid dose
Description: Mid dose of EO2002 (magnetic human corneal endothelial cells)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EO2002 high dose
Description: High dose of EO2002 (magnetic human corneal endothelial cells)
Study: NCT06422468

Intervention type: DEVICE
Group type: OTHER
Intervention: FibriCheck recordings
Description: PPG, ACC, GYR, ECG and sound measurements
Study: NCT04874285

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HA
Description: hyaluronic acid, alpha-lipoic acid, vitamin D and vitamin B6
Study: NCT04850677

Intervention type: OTHER
Intervention: Observational Cohort
Description: Observational study